EASD Abstract SIDS 28032019.docx (278.75 kB)
Download file

The metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes

Download (278.75 kB)
conference contribution
posted on 13.05.2020, 13:32 by R Herring, F Shojaee-Moradie, R Garesse, M Stevenage, N Jackson, C Lucy, BA Fielding, A Umpleby, DL Russell-Jones, M Davies
The metabolic effects of an SGLT2 inhibitor (dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes

History

Citation

Diabetologia, 2019, 62 (Suppl 1), pp. S124-S124 (1)

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research Centre

Source

55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Barcelona, SPAIN

Published in

Diabetologia

Volume

62

Issue

Suppl 1

Pagination

S124-S124 (1)

Publisher

SPRINGER

issn

0012-186X

eissn

1432-0428

Copyright date

2020

Available date

05/08/2020

Publisher version

https://link.springer.com/article/10.1007/s00125-019-4946-6

Spatial coverage

Barcelona, Spain

Temporal coverage: start date

16/09/2019

Temporal coverage: end date

20/09/2019

Language

en